Gsa Capital Partners LLP Ngm Biopharmaceuticals Inc Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	SELL	$1.17 - $1.92 $352,104 - $577,812	-300,944 Reduced 89.98%	33,529 $53,000
Q4 2023 Feb 16, 2024	BUY	$0.6 - $1.31 $72,478 - $158,244	120,797 Added 56.53%	334,473 $287,000
Q3 2023 Nov 15, 2023	SELL	$1.05 - $3.37 $112,597 - $361,385	-107,236 Reduced 33.42%	213,676 $228,000
Q2 2023 Aug 14, 2023	SELL	$2.44 - $4.53 $264,879 - $491,763	-108,557 Reduced 25.28%	320,912 $831,000
Q1 2023 May 12, 2023	BUY	$3.72 - $5.4 $1.12 Million - $1.62 Million	300,190 Added 232.2%	429,469 $1.75 Million
Q4 2022 Feb 13, 2023	BUY	$3.41 - $12.93 $403,130 - $1.53 Million	118,220 Added 1068.99%	129,279 $649,000
Q3 2022 Nov 14, 2022	BUY	$12.59 - $17.67 $139,232 - $195,412	11,059 New	11,059 $145,000
Q1 2021 May 10, 2021	SELL	$24.99 - $31.93 $1.17 Million - $1.5 Million	-46,908 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$16.21 - $31.44 $760,378 - $1.47 Million	46,908 New	46,908 $1.42 Million

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.